about
Characteristics and Patterns of Rare Malignancies Published in Rare TumorsMulti-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer.Demonstration of a software design and statistical analysis methodology with application to patient outcomes data sets.Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.Primary pineal tumors: outcome and prognostic factors--a study from the Rare Cancer Network (RCN).Langerhan's Cell Sarcoma: Two Case Reports.Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CA.Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]).Testicular cancer survivorship: research strategies and recommendations.History of the rare cancer network and past research.Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).Incidence of brain metastasis in patients with esophageal carcinoma.Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study.Outcomes of stereotactic body radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules.Rare presentations of primary melanoma and special populations: a systematic review.Influence of patient's physiologic factors and immobilization choice with stereotactic body radiotherapy for upper lung tumors.Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative studyRadiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network.Acute and late toxicities of radiotherapy for patients with discoid lupus erythematosus: a retrospective case-control study.Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993).Genetic testing for young-onset colorectal cancer: case report and evidence-based clinical guidelinesRecurrent invasive lobular carcinoma presenting as a ruptured breast implant.Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma.Curing patients with locally advanced esophageal cancer: an update on multimodality therapy.Impact of endoscopic ultrasonography and physician specialty on the management of patients with esophagus cancer.Extraskeletal Osteosarcoma: An International Rare Cancer Network Study.N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy.Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CAAdjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005).Evidence-based guidelines for adjuvant therapy for resected adenocarcinoma of the pancreas.Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study.Is a solitary inguinal lymph node metastasis from adenocarcinoma of the rectum really a metastasis?Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis.Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee.Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE.Position statement on ethics, equipoise and research on charged particle radiation therapy.Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: A retrospective review from a large academic center.
P50
Q26738603-8E136431-52EA-423C-B5C1-A90037B9B9D0Q30459120-24C0EE52-8849-4538-A560-E1F3DE57BBE4Q30711507-2ECE919B-030B-499C-9942-DA3737105BEDQ33377344-233F305A-FE08-4AB5-9158-7BB01E1ED88EQ33402930-19490F3E-BBA7-4D67-B03B-00478EA50EA4Q33431898-3AAFD086-1E01-4855-96CC-33AAB09D61BCQ33601615-FEF8E8A8-E916-4076-9468-529306896624Q33633414-CD0FCB1B-096F-408F-AA5C-5C2D9EC34298Q34039684-42FBCF6E-D257-4DF0-9FC0-C60C77A918CBQ34259200-C6EC3BE8-ABA5-4C6F-8EDC-37260165CEEEQ34367737-8B534947-76D5-4E12-A8F5-23E83520FF09Q34728110-59527DB1-2643-4660-A87C-E5DD1ABE9CDBQ35012664-FF132735-0FC9-4B21-ADDC-BD1018263D67Q35112046-C3FE456A-0273-4A3A-909F-C8C7749D7848Q35124684-B505D2A8-C99C-4344-A6EC-75B484CBE36AQ35147046-5EBEE926-BF6B-4205-9E6D-452784B5EB26Q35245587-41D5211F-A4BE-473C-B38B-A6AAF445386AQ35477482-6F1160B6-3CBF-4F7F-90A2-0258AA5FB22EQ35532111-492F151B-C139-4908-9908-75A1A2B456BCQ35788836-D96DEAB0-8A86-4ED0-AA60-2FDBCF9C1FB0Q35812063-8EEAF250-65A4-41C1-B9EF-E6A283683B30Q36080860-35DD1D09-06CA-4301-A3CC-8AC1BD5C570BQ36177617-85F57E51-A9D9-4CCB-B983-87B05C9735DDQ36177879-1F133142-4357-46D2-B7AB-60D9B5C949EFQ36299709-43FAF3FC-8284-4E9D-ACFD-9A0FB7E662A5Q36636703-0A199322-E198-4873-83A6-BBBB68315BACQ36959768-DA8F08C0-75CF-4E8F-91B3-67111DE88E88Q36967766-B0FCD3C7-46FF-4BF3-AFA8-78950A8D63CEQ37114350-EEFCEC72-C6C1-4FF6-BD05-D4E9BF7F89E2Q37119415-C5CB8750-716F-417B-9060-0F3264A6F61BQ37221905-6CAD636A-3694-4D98-9C2E-71DD196A23D3Q37233957-171584AE-DA0E-45CC-9644-5FB442B6BB10Q37339684-5272200C-DEC3-4A7F-8A77-9485EEFE4938Q37403719-131407F1-F777-47D2-BD2A-3A30B9A49D8AQ37593250-1C6753D2-E7BC-4EAC-B067-C4503E29E8AAQ37680020-1CAA1624-3B27-43E1-811B-BC1A2A3A2B48Q37719072-762DBDCE-CD77-45B3-B497-243EF3D48B0AQ38058168-6A48AAEA-2848-470F-A83A-98896E8DFF9CQ38138821-750E020D-B30E-451F-B6CE-0AEA34A18AF5Q38199821-95EAEF77-03C0-4678-80A8-6AD32FBEA281
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Robert C Miller
@nl
Robert C Miller
@sl
Robert C. Miller
@en
Robert C. Miller
@es
type
label
Robert C Miller
@nl
Robert C Miller
@sl
Robert C. Miller
@en
Robert C. Miller
@es
prefLabel
Robert C Miller
@nl
Robert C Miller
@sl
Robert C. Miller
@en
Robert C. Miller
@es
P106
P1153
55687130600
P21
P31
P3835
robert-miller22
P496
0000-0001-8932-2732